NEW YORK--(Business Wire)--Reportlinker.com announces that a new market research report
related to the Pharmaceutical industry is available in its catalogue.
Genzyme Corporation: Company Profile
To order that report:
www.reportlinker.com/p073698
/Genzyme-Corporation-Company-Profile.html
(Due to its length, this URL may need to be copied/pasted into
your Internet browser's address field. Remove the extra space if one
exists.)
For more information, contact Nicolas by email
nbo@reportlinker.com , by phone +33 4 37 65 17 03.
This analysis examines the historical and forecast performance for
Genzyme in the ethical pharmaceutical sector. The profile encompasses
global company strategy, portfolio and pipeline analysis and
assessment of financial performance, with 1-6 year sales forecasts for
key drugs. An interactive forecasting and analysis tool provides
continually updated quantitative and qualitative information.
Benchmark Genzyme's performance against key rivals in the ethical
pharmaceutical sector. Analyze how an anticipated increase in
competition for the Gaucher's treatment Cerezyme will drive
therapeutic diversification. Assess the company's steady expansion of
revenues generated via the oncology market
CHAPTER 1 EXECUTIVE SUMMARY 2
Key findings 2
Historical and forecast ethical sales performance 3
Therapeutic strategy 5
Therapeutic strategy 5
Launch and expiry outlook 8
Externalization, geographic and molecule type strategies 11
Externalization strategy 12
Geographic strategy 13
Molecule type strategy 13
SWOT analysis 15
Strengths 15
Weaknesses 16
Opportunities 17
Threats 17
CHAPTER 2 CORPORATE HISTORY 22
Key findings 22
Background 23
Key corporate developments 24
M&A history 25
M&A history 25
ILEX Oncology 26
Bone Care International 26
AnorMED acquisition 27
Mozobil-the catalyst 27
Bioenvision 28
Current corporate structure 29
Biotherapeutics 29
Lysosomal storage disorders 30
Genetics/diagnostics 31
Current management team 32
CHAPTER 3 HISTORICAL PERFORMANCE 33
Key findings 33
Introduction 34
Revenue and growth rate analysis, 2001-06 34
Revenue and growth rate vs. peer set 35
Product analysis, 2001-06 39
Product analysis, 2001-06 39
Growth drivers 39
Cerezyme 39
Fabrazyme 40
Renagel 40
Synvisc 40
Operating revenue and cost analysis, 2001-06 41
Operating revenue/cost analysis 43
CHAPTER 4 FORECAST PERFORMANCE 45
Key findings 45
Introduction 46
Revenue and growth rate, 2006-12 46
Product analysis, 2006-12 47
Growth drivers 51
Myozyme 51
Renagel/Renvela 52
Clolar 52
Fabrazyme 52
Synvisc 52
Therapy area analysis, 2006-12 54
Endocrine, metabolic and genetic disorders 57
Cardiovascular & hematology 57
Oncology 58
Therapy area focus 59
Launches and expiries analysis, 2006-12 62
Launch portfolio 62
Expiry portfolio 65
Launch/core/expiry configuration 67
Externalization analysis, 2006-12 70
Geographic analysis, 2006-12 75
Geographic analysis, 2006-12 75
Molecule type analysis, 2006-12 79
Molecule type analysis, 2006-12 79
CHAPTER 5 KEY PRODUCTS AND COMPETITORS 84
Key findings 84
Overview 85
Endocrine, metabolic & genetic disorders 86
Cerezyme 86
Overview 86
Sales forecast 87
Newsflow 87
Competitive landscape 88
Fabrazyme 91
Overview 91
Sales forecast 92
Newsflow 92
Competitive landscape 93
Myozyme 95
Overview 95
Sales forecast 96
Newsflow 96
Competitive landscape 96
Cardiovascular & hematology 99
Renagel/Renvela 99
Overview 99
Sales forecast 100
Newsflow 100
Competitive landscape 101
Oncology 104
Clolar 104
Overview 104
Sales forecast 105
Newsflow 105
R&D pipeline 108
CHAPTER 6 APPENDIX 109
IMS vs. company-reported data reconciliation 109
References 109
Datamonitor Reports 109
Abbreviations 110
List of Tables
Table 1: Genzyme Group Corporate Executive Committee 32
Table 2: Peer set overview 35
Table 3: Operating revenue/cost analysis ($m), 2001-06 41
Table 4: Operating cost ratio analysis (% of total revenues),
2001-06 43
Table 5: Product portfolio overview, sales ($m), 2006-12 48
Table 6: Therapy area overview, sales ($m), 2006-12 54
Table 7: Launch portfolio overview, sales ($m), 2006-12 62
Table 8: Core portfolio overview, sales ($m), 2006-12 64
Table 9: Expiry portfolio overview, sales ($m), 2006-12 65
Table 10: Externally developed portfolio ($m), 2006-12 70
Table 11: Molecule type overview, sales ($m), 2006-12 79
Table 12: Key products overview 85
Table 13: Cerezyme: overview 86
Table 14: Cerezyme: sales forecast ($m), 2006-12 87
Table 15: Cerezyme: newsflow 87
Table 16: Fabrazyme: overview 91
Table 17: Fabrazyme: sales forecast ($m), 2006-12 92
Table 18: Fabrazyme: newsflow 92
Table 19: Myozyme: overview 95
Table 20: Myozyme: sales forecast ($m), 2006-12 96
Table 21: Myozyme: newsflow 96
Table 22: Renagel/Renvela: overview 99
Table 23: Renagel/Renvela: sales forecast ($m), 2006-12 100
Table 24: Renagel/Renvela: newsflow 100
Table 25: Clolar: overview 104
Table 26: Clolar: sales forecast ($m), 2006-12 105
Table 27: Clolar: newsflow 105
Table 28: Genzyme's R&D pipeline (Phase I-registration) 108
List of Figures
Figure 1: Historical and forecast ethical sales performance (%
CAGR), Genzyme and biotechnology peer set 3
Figure 2: Therapeutic focus vs. biotechnology peer set (%), 2006 6
Figure 3: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Genzyme 8
Figure 4: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set 9
Figure 5: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2006 11
Figure 6: Molecule type, externalization and geographic market
dependency (%) vs. peer set, 2012 12
Figure 7: SWOT analysis of Genzyme 15
Figure 8: Genzyme timeline 24
Figure 9: M&A/divestment history 25
Figure 10: Current corporate structure 29
Figure 11: Revenue & growth rate (ethical sales) ($m), 2001-06 34
Figure 12: Ethical revenue ($m) and growth rate (%) vs. peer set,
2001-06 37
Figure 13: Growth drivers/resistor products of historical revenue
performance ($m), 2001-06 39
Figure 14: Operating revenue/cost analysis ($m), 2001-06 42
Figure 15: Operating cost ratio analysis (% of total revenues),
2001-06 44
Figure 16: Ethical revenue ($m) and growth rate (%), 2006-12 46
Figure 17: Top five products by sales ($m), 2006 49
Figure 18: Top five products by sales ($m), 2012 50
Figure 19: Growth drivers and resistors by product, 2006-12 51
Figure 20: Key strategic products, sales ($m), 2006-12 53
Figure 21: Ethical sales by therapy area ($m), 2006-12 56
Figure 22: Growth drivers and resistors by therapy area ($m),
2006-12 57
Figure 23: Ethical sales by therapy area (%), 2006-12 59
Figure 24: Therapy area focus compared with peer set (% total
ethical sales), 2006 60
Figure 25: Therapy area focus compared with peer set (% total
ethical sales), 2012 61
Figure 26: Launch schedule, sales ($m), 2006-12 63
Figure 27: Core products sales growth ($m), 2006-12 65
Figure 28: Expiry schedule, sales ($m), 2006-12 66
Figure 29: Launch, core and expiry, sales ($m), 2006-12 67
Figure 30: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), Genzyme 68
Figure 31: Launch, core and expiry, absolute sales growth, 2006-12
(sales as % of 2006 sales), peer set 69
Figure 32: Externalization dependency, sales ($m), 2006-12 71
Figure 33: Growth drivers and resistors, externally vs. internally
discovered products, sales ($m), 2006-12 72
Figure 34: Externalization dependency vs. peer set, % total sales,
2006 73
Figure 35: Externalization dependency vs. peer set, % total sales,
2012 74
Figure 36: Geographical sales breakdown ($m), 2006-12 75
Figure 37: Growth drivers and resistors by geography, sales ($m),
2006-12 76
Figure 38: US dependency vs. peer set, % total sales, 2006 77
Figure 39: US dependency vs. peer set, % total sales, 2012 78
Figure 40: Growth drivers and resistors by molecule type, sales
($m), 2006-12 80
Figure 41: Molecule type sales breakdown ($m), 2006-12 81
Figure 42: Biologics dependency vs. peer set, % total sales, 2006
82
Figure 43: Biologics dependency vs. peer set, % total sales, 2012
83
To order that report:
www.reportlinker.com/p073698
/Genzyme-Corporation-Company-Profile.html
(Due to its length, this URL may need to be copied/pasted into
your Internet browser's address field. Remove the extra space if one
exists.)
For more information, contact Nicolas by email
nbo@reportlinker.com , or by phone +33 4 37 65 17 03.
More market research reports?
Go to http://www.reportlinker.com
Reportlinker
Nicolas, +33 4 37 65 17 03
nbo@reportlinker.com
Copyright Business Wire 2008
